We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice for medical professionals to follow when assessing drivers with psychiatric disorders.
Healthcare professionals prescribing fluoroquinolone antibiotics (ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ofloxacin) are reminded to be alert to the risk of psychiatric reactions, including depression and psychotic reactions, which may potentially lead to thoughts of suicide or suicide attempts. Healthcare professionals are...
The CMA investigated alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
Employment Tribunal decision.
Public Health England study finds people with learning disabilities are regularly prescribed psychiatric drugs without a recorded diagnosis.
The CMA has completed its investigation into anti-competitive agreements in the pharmaceutical sector under Chapter I CA98 (case reference: 50511-2).
The CMA has issued decisions imposing fines on suppliers of nortriptyline tablets for breaching competition law.
The CMA is investigating alleged anti-competitive agreements in the pharmaceutical sector under Chapter I CA98 (case reference: 50511-1).
The CMA has provisionally found that 4 pharmaceutical companies broke competition law in relation to the supply of an anti-depressant drug.
The CMA is investigating alleged anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
Upper Tribunal Administrative Appeals Chamber decision by Judge Knowles on 11 March 2016.
The CMA today alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).